HTGF | High-Tech Gruenderfonds

Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.

Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform offers user-friendly software that supports healthcare staff in their daily operations while facilitating the integration of innovative technologies such as artificial intelligence, big data, telemedicine, patient applications, and wearables. By streamlining workflows and automating various tasks, Avelios Medical aims to significantly improve both patient outcomes and healthcare research, making it a valuable resource for hospitals and clinics seeking to modernize their services.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

inContAlert is a deep tech start-up disrupting the field of incontinence. The technology of inContAlert helps people with bladder dysfunction to monitor the filling level of their urinary bladder. -- no more unnecessary catheters. no more needless emptying through nurses. no more diapers -- inContAlert, therefore, developed an mHealth device, which collects and analyzes data with the help of deep learning algorithms. The information is then displayed on an app and sends an alert to incontinence patients when a predefined filling level is reached. inContAlert thereby minimizes the risk of an uncontrolled loss of urine or the harmful distension of the bladder. With the help of inContAlert, incontinence patients can go back to normal and live a carefree life.

DNTOX operates a bioanalytical testing laboratory focused on animal-free screening of chemicals, particularly for their potential to disrupt brain development and cause developmental neurotoxicity. The laboratory utilizes an in vitro testing battery based on human cell models, which facilitates high-content and medium-throughput chemical screening. This process is enhanced by proprietary software that employs artificial intelligence, aiding clients in the chemical, pharmaceutical, and cosmetics industries. DNTOX supports its customers in identifying safe lead structures during substance development and conducting safety assessments during the approval and re-approval processes of chemicals. The company's commitment to innovation aims to promote the use of safe chemicals without the reliance on animal testing.

Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.

Mbiomics is a biotechnology company focused on microbiome research, diagnostics, and therapeutics. It has developed a high-throughput, low-cost platform that allows for dynamic and real-time analysis and quantification of the human gut microbiome. By providing informed precision diagnostics and targeted therapies, Mbiomics aims to enhance patient outcomes and promote healthier living through innovative approaches.

HBOX Therapies is a developer of technology that facilitates the lung-protective treatment of respiratory patients. They produce miniaturized hyperoxygenation therapies. The technology's application is miniature respiratory assistance for patients suffering from lung failure.

Neotiv GmbH, founded in 2017 and headquartered in Magdeburg, Germany, specializes in mobile software solutions aimed at monitoring memory function and supporting individuals with dementia. The company offers memory tests designed to assess brain regions affected by aging and early Alzheimer's disease. Its health monitoring application not only tracks users' memory performance over time but also provides insights derived from scientific research, making them accessible to a wider audience. By combining neurodegenerative disease research with its digital platform, Neotiv enables healthcare professionals and researchers to enhance early detection and management of memory-related issues.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for the identification and assessment of pathogens associated with bloodstream infections. The company utilizes Next Generation Sequencing (NGS) to enable intensive care clinicians to detect bacteria, fungi, viruses, and parasites from a single standard blood draw, without the need for prior cultivation or detailed knowledge of the infection's nature. Its proprietary algorithms assess the relevance of each identified pathogen, allowing for precise differentiation between commensals, contamination, and actual infection. Noscendo's innovative platform aims to enhance the efficiency and accuracy of pathogen detection in clinical settings.

M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform offers user-friendly software that supports healthcare staff in their daily operations while facilitating the integration of innovative technologies such as artificial intelligence, big data, telemedicine, patient applications, and wearables. By streamlining workflows and automating various tasks, Avelios Medical aims to significantly improve both patient outcomes and healthcare research, making it a valuable resource for hospitals and clinics seeking to modernize their services.

mediaire GmbH is a software for computer-based diagnosis in radiology was developed, which is locally installed

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

Loewi GmbH, established in 2019 and based in Munich, Germany, operates an online platform that specializes in the sale of non-pharmacy medical products, including medical self-tests and health products. As a scientific spin-off from the Technical University of Munich, Loewi aims to make personalized health and nutrition accessible to a broader audience. The company emphasizes a healthy and active lifestyle by offering personalized diet recommendations and supplements tailored to individual needs based on test results. With a strong focus on scientific evidence and data-driven personalization, Loewi leverages methods developed and tested in competitive sports to analyze nutrient requirements and help customers achieve their health goals. The integration of science and technology underpins Loewi's operations, and the company collaborates with leading universities and research institutions to advance the industry.

PXL Vision AG, founded in 2017 and headquartered in Zurich, Switzerland, specializes in the design and development of identity verification and customer onboarding software solutions. Its flagship product, Daego, employs advanced computer vision and machine learning technologies to create trusted digital identities. This cross-platform solution is tailored to meet the needs of various industries, including insurance, fintech, and healthcare, by automating the verification of identity documents and performing facial biometric checks to ensure that users are legitimate and the rightful owners of their documents. By facilitating secure and efficient customer onboarding, PXL Vision aims to enhance conversion rates, reduce costs associated with compliance, and mitigate identity fraud. With research and development centers in Novi Sad, Serbia, and Yerevan, Armenia, PXL Vision is dedicated to establishing a foundation of trust in digital interactions through unbiased and verifiable identities.

Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for the identification and assessment of pathogens associated with bloodstream infections. The company utilizes Next Generation Sequencing (NGS) to enable intensive care clinicians to detect bacteria, fungi, viruses, and parasites from a single standard blood draw, without the need for prior cultivation or detailed knowledge of the infection's nature. Its proprietary algorithms assess the relevance of each identified pathogen, allowing for precise differentiation between commensals, contamination, and actual infection. Noscendo's innovative platform aims to enhance the efficiency and accuracy of pathogen detection in clinical settings.

Mecuris strives to be the key enabler for digitally manufactured O&P solutions worldwide. They empower O&P professionals to co-create customised O&P products and enrich wearer’s lives within 24 hours.To reach this goal, they team up with O&P professionals to co-create - with users and wearers - customised O&P products. Their digital mindset and 3D printing know-how synergise in the Mecuris Solution Platform, which simplifies the work of O&P professionals and enriches wearers’ lives. The Mecuris Solution Platform uses patient data and scans to semi-automatically individualise 3D designs of patient aids. It makes them ready-to-print at a local 3D printing hub. This enables a 100% customised fit, functionality and look. They thereby cut production times by 75% for the medical practitioners and wearers.

M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

miRdetect GmbH is a Bremen-based company that specializes in the development and marketing of in-vitro diagnostics for cancer detection. Founded in 2016, the company offers products such as miRcontrol GCT, a test kit specifically designed for the detection of testicular cancer. miRdetect focuses on creating and manufacturing molecular biological tests that enable the early identification and diagnosis of various cancers by accurately detecting minute quantities of nucleic acids. In addition to its existing products, the company is actively engaged in research and development to expand its portfolio of diagnostic tests.

mediaire GmbH is a software for computer-based diagnosis in radiology was developed, which is locally installed

The only "chemoselective" sense of human kind is the sense of smell. Through this sense They are able to perceive taste, aroma, and hazardous substances, such as hydrogen sulfide. Unfortunately, this sense is evolutionarily hampered for human beings compared to animals like dogs, for instance. Also from a technological perspective there is no sensitive and selective "electronic nose" available, yet. Therefore, thay are strive to provide a novel sensor technology based on ambient mass spectrometry which does not only improve the utilization in traditional laboratory environments, but also enables the transfer of this kind of sensor technology to industrial process control, forensics, security technology (drugs, explosives, etc.) and the medical "point of care" diagnostics.

Mecuris strives to be the key enabler for digitally manufactured O&P solutions worldwide. They empower O&P professionals to co-create customised O&P products and enrich wearer’s lives within 24 hours.To reach this goal, they team up with O&P professionals to co-create - with users and wearers - customised O&P products. Their digital mindset and 3D printing know-how synergise in the Mecuris Solution Platform, which simplifies the work of O&P professionals and enriches wearers’ lives. The Mecuris Solution Platform uses patient data and scans to semi-automatically individualise 3D designs of patient aids. It makes them ready-to-print at a local 3D printing hub. This enables a 100% customised fit, functionality and look. They thereby cut production times by 75% for the medical practitioners and wearers.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

Asana Rebel is a Berlin-based startup founded in 2015 by Pascal Klein and Robin Pratap, offering a Yoga-inspired fitness app that combines elements of yoga and traditional fitness. The app provides users with access to a variety of personalized workouts designed by fitness and yoga experts, along with curated collections aimed at helping individuals achieve specific fitness goals. Available in six languages—German, English, French, Portuguese, Spanish, and Italian—the app has been well-received, consistently rated above 4.6 out of 5 stars on various platforms. Asana Rebel has also gained recognition from major app stores, being featured multiple times by both Apple and Google as one of the leading health and fitness applications.

advanceCOR is a clinical drug developing company that focuses on therapeutics and diagnostics for heart and vascular diseases. Its products include Revacept, a human Fc fusion protein, which prevents the local activation of platelets at sites of vascular injury; COR-2, a recombinant protein that interferes with the generation of foam cells; and COR-3, a recombinant protein, which specifically binds to atherosclerotic plaques, and then bi-specifically binds to circulating progenitor cells to trap the endogenously occurring progenitor cells for accelerated plaque healing.

Neotiv GmbH, founded in 2017 and headquartered in Magdeburg, Germany, specializes in mobile software solutions aimed at monitoring memory function and supporting individuals with dementia. The company offers memory tests designed to assess brain regions affected by aging and early Alzheimer's disease. Its health monitoring application not only tracks users' memory performance over time but also provides insights derived from scientific research, making them accessible to a wider audience. By combining neurodegenerative disease research with its digital platform, Neotiv enables healthcare professionals and researchers to enhance early detection and management of memory-related issues.

Asana Rebel is a Berlin-based startup founded in 2015 by Pascal Klein and Robin Pratap, offering a Yoga-inspired fitness app that combines elements of yoga and traditional fitness. The app provides users with access to a variety of personalized workouts designed by fitness and yoga experts, along with curated collections aimed at helping individuals achieve specific fitness goals. Available in six languages—German, English, French, Portuguese, Spanish, and Italian—the app has been well-received, consistently rated above 4.6 out of 5 stars on various platforms. Asana Rebel has also gained recognition from major app stores, being featured multiple times by both Apple and Google as one of the leading health and fitness applications.

M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.

Mecuris strives to be the key enabler for digitally manufactured O&P solutions worldwide. They empower O&P professionals to co-create customised O&P products and enrich wearer’s lives within 24 hours.To reach this goal, they team up with O&P professionals to co-create - with users and wearers - customised O&P products. Their digital mindset and 3D printing know-how synergise in the Mecuris Solution Platform, which simplifies the work of O&P professionals and enriches wearers’ lives. The Mecuris Solution Platform uses patient data and scans to semi-automatically individualise 3D designs of patient aids. It makes them ready-to-print at a local 3D printing hub. This enables a 100% customised fit, functionality and look. They thereby cut production times by 75% for the medical practitioners and wearers.

Bentekk GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development and manufacture of intelligent gas measuring systems aimed at on-site analysis of contaminants. The company produces portable gas measurement devices that utilize gas chromatography and photo ionization detection for the assessment of volatile organic compounds, including hazardous substances like benzene. These devices are designed to enhance occupational health and safety across various sectors, including environmental monitoring, emergency response, logistics, life sciences, and the chemical industry. By providing accurate and rapid measurements of toxic gases, Bentekk supports improved safety and compliance with threshold limit values, contributing to a safer working environment. As of April 2017, Bentekk operates as a subsidiary of Dräger Safety AG & Co. KGaA.

Asana Rebel is a Berlin-based startup founded in 2015 by Pascal Klein and Robin Pratap, offering a Yoga-inspired fitness app that combines elements of yoga and traditional fitness. The app provides users with access to a variety of personalized workouts designed by fitness and yoga experts, along with curated collections aimed at helping individuals achieve specific fitness goals. Available in six languages—German, English, French, Portuguese, Spanish, and Italian—the app has been well-received, consistently rated above 4.6 out of 5 stars on various platforms. Asana Rebel has also gained recognition from major app stores, being featured multiple times by both Apple and Google as one of the leading health and fitness applications.

We develop innovative in vitro diagnostic tests for neurodegenerative disorders.

LifeTime is a digital health application developed by connected-health.eu GmbH since 2014, which has established itself as a leading and secure solution for the digital management and transmission of medical data. The application facilitates the efficient and accurate exchange of medical documents, including findings and images, between healthcare professionals and patients. By enabling secure digital communication, LifeTime enhances the clarity of health and treatment histories for users, streamlining workflows for doctors and medical staff. In 2019, LifeTime GmbH acquired the platform, signaling a new phase of development and enhancement under its management.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

Preventicus GmbH, founded in 2014 and headquartered in Jena, Germany, develops innovative health solutions that utilize smartphone and smartwatch technologies to monitor vital parameters. The company's main product, Preventicus Heartbeats, is a class I medical device designed to identify atrial fibrillation, a condition that increases the risk of stroke. This smart screening solution allows users to check their heart rhythm quickly and conveniently, requiring no additional accessories. The software applications are certified medical devices and have demonstrated a level of accuracy previously achievable only by physicians, making them valuable for private users, corporate clients in occupational health management, and OEM customers. Preventicus focuses on early preclinical risk screening for lifestyle-related illnesses, including heart attacks and strokes, effectively enhancing personal health management.

EGYM is a global fitness technology company that specializes in providing intelligent workout solutions for fitness and health facilities. Its platform integrates connected gym equipment with software to enhance the workout experience for gym operators and their members. EGYM offers a B2B corporate fitness subscription solution aimed at employers, along with personalized, data-driven fitness experiences for gym users. This approach enables individuals to pursue various training goals, including muscle gain, performance enhancement, and rehabilitation. By focusing on member success, EGYM aims to facilitate gym success, promoting a healthier lifestyle and improved physical and mental wellness for all users.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

Synoste Oy, founded in 2007 and based in Espoo, Finland, specializes in developing innovative solutions for the treatment of skeletal deformities. The company focuses on patient-friendly technologies for various conditions, including congenital limb discrepancies, trauma-related injuries, and craniomaxillofacial deformities. Its flagship product is a third-generation limb-lengthening system that incorporates smart materials, designed to enhance patient comfort during the often-complicated lengthening procedure. This advanced device aims to reduce complications and facilitate quicker recovery, making it a significant improvement over traditional methods. As a subsidiary of Globus Medical, Inc., Synoste continues to advance its mission of providing effective and less painful treatment options for individuals with skeletal deformities.

Photonics Healthcare GmbH is a medical device company based in Garching, Germany, specializing in the development and commercialization of clinical monitors for measuring cellular oxygen levels. Its primary product, the COMET Monitor, enables healthcare professionals to non-invasively assess cellular oxygen metabolism, including both availability and consumption, at the bedside. This technology is crucial for detecting hypoxia in tissue cells, allowing doctors to evaluate tissue vitality and make informed decisions regarding treatment interventions. By providing real-time data on cellular oxygen dynamics, Photonics Healthcare supports the timely prevention of organ failure and aims to enhance patient care. Additionally, the company offers contract research programs to further advance its medical technologies.

AYOXXA Biosystems GmbH is a life science tools company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in developing a proprietary technology platform for multiplexed protein analysis. This platform, which utilizes In-situ Encoded Bead-based Arrays, enables users to simultaneously measure multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's innovative biochips merge biological analysis with information technology, expanding the potential applications in biomedical research. The company also offers biomarker kits to facilitate the identification and quantification of proteins and other biomolecular analytes.

OakLabs is a research firm that conducts and offers a range of laboratory procedures and computing expertise to its clients. The company’s range of services consist of Biocomputing, MyArray, and gene expression. Biocomputing offers design and conceptual realization in terms of sequence analysis, genomic selection, and biomolecule simulation. MyArray services consist of XL-design development, RNA and DNA sample hybridization, and selection. OakLabs was founded in 2011 by Martina Schad.

Eyesight & Vision GmbH, founded in 2010 and based in Nürnberg, Germany, specializes in the development and marketing of advanced diagnostic equipment for refractive errors during cataract surgery. The company’s flagship product, the Intraoperative Ocular Wavefront Aberrometer (I-O-W-A), enables surgeons to optimize the selection and positioning of intraocular lenses (IOLs) with enhanced predictability of refractive outcomes and improved patient satisfaction. Utilizing patented "flying spot" technology, the system provides real-time measurements of refractive power and incorporates binocular input reflection through a 3D Head-Up Display, ensuring seamless integration with existing surgical microscopes. This innovative approach facilitates efficient and accurate measurements during surgery, ultimately contributing to better surgical results.

Capical GmbH specializes in the development and marketing of advanced electrocardiography (ECG) devices that utilize capacitive electrodes for contact-free patient monitoring. Founded in 2010 and based in Braunschweig, Germany, the company has established itself as a leader in capacitive sensor technology, which has applications beyond healthcare, including monitoring driver states in vehicles and physiological parameters in furniture such as chairs and beds. Capical's innovative approach allows for the continuous monitoring of heart and respiratory rates, cardiac arrhythmias, and other vital signs without direct skin contact, enhancing patient comfort and safety. The company also engages in extensive research and development to integrate its monitoring solutions into various products, supporting clients from initial prototyping to serial production. Capical has received several awards for its technological advancements and is recognized for its pioneering work in medically approved capacitive ECG devices, aiming to improve quality of life for elderly and ill individuals while also enhancing safety in automated driving scenarios.

Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the management and treatment of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, ready-to-use elispot kits, and various assay development services. Lophius Biosciences utilizes proprietary technologies, such as T-activation® and Reverse T Cell Technology, to stimulate immune effector cells and differentiate between active and memory T cells. These advancements support personalized treatment approaches and improve therapy control for patients, particularly in the fields of transplantation and infectious disease management. Additionally, the company provides custom services for bioactivity and quality testing of pharmaceutical agents, highlighting its commitment to advancing research and diagnostics in immunology.

Biametrics products are designed to provide solutions with unmatched performance in terms of throughput and versatility for scientists in the academia, pharmaceutical, biotechnology, and diagnostic markets. Biametrics label free systems characterize biomolecular interactions in terms of kinetic and affinity data (KD, ka, kd), specificity, concentration and thermodynamic data (enthalpy and entropy).

ChromoTek GmbH, founded in 2008 and based in Planegg-Martinsried, Germany, specializes in the development of innovative immunologic research reagents and tools for proteomics and cell biology. The company focuses on creating a new class of research tools derived from single domain camel antibodies, which are designed to enhance research capabilities in health institutions globally. By providing advanced tools for scientific research, ChromoTek aims to improve the quality and effectiveness of research outputs in the fields of cell biology and proteomics.

Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the management and treatment of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, ready-to-use elispot kits, and various assay development services. Lophius Biosciences utilizes proprietary technologies, such as T-activation® and Reverse T Cell Technology, to stimulate immune effector cells and differentiate between active and memory T cells. These advancements support personalized treatment approaches and improve therapy control for patients, particularly in the fields of transplantation and infectious disease management. Additionally, the company provides custom services for bioactivity and quality testing of pharmaceutical agents, highlighting its commitment to advancing research and diagnostics in immunology.

Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes. LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally.

Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.

Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the management and treatment of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, ready-to-use elispot kits, and various assay development services. Lophius Biosciences utilizes proprietary technologies, such as T-activation® and Reverse T Cell Technology, to stimulate immune effector cells and differentiate between active and memory T cells. These advancements support personalized treatment approaches and improve therapy control for patients, particularly in the fields of transplantation and infectious disease management. Additionally, the company provides custom services for bioactivity and quality testing of pharmaceutical agents, highlighting its commitment to advancing research and diagnostics in immunology.

Sense Inside develops a unique diagnostic and therapeutic device specifically for bruxism, the condition characterized by involuntary teeth grinding. This innovative device aims to offer long-term solutions for both diagnosis and treatment, addressing the significant physiological strain experienced by an increasing number of patients. By equipping healthcare professionals with a comprehensive tool, Sense Inside enhances the ability to diagnose and manage dental diseases associated with bruxism.

awenydd diagnostics GmbH is a Germany-based company that analyzes patients and interactions they have with other drugs.

Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.

Scylab medic develops an environment sensing device for blind and visually impaired people. Its products include feelix, a light device that uses a 3D sensor to facilitate the user to partially recognize surroundings without physically touching, as well as to identify stationary and moving objects. The company was founded in 2006 and is based in Leipzig, Germany.

multiBIND biotec GmbH, founded in 2005 and located in Dortmund, Germany, specializes in developing innovative solutions for decontamination and disinfection. The company’s flagship technology, bioDECONT®, addresses issues related to horizontal gene transfer by effectively removing genetic material (DNA/RNA) and various biomolecules, including proteins and lipids. Additionally, multiBIND offers bioCLEAN, a range of antimicrobial and antiviral solutions, and CleanExtract, a tool designed for rapid determination of microbial ATP in diverse substances such as lubricants, oil emulsions, and paint. Through its focus on molecular genetics and biomedicine, multiBIND biotec aims to advance technologies and products that enhance safety and cleanliness in various applications.